The CERES scores of other genes, such as RAF1, ABCB11, LIG3, and IARS, were less than 0 in most AML cell lines, suggesting that AML patients with poorer prognosis may benefit from treatment targeting these genes. This evidence concerns the gene LIG3 and acute myeloid leukemia.